Is AC Immune SA (ACIU)’s Fuel Running Low? The Stock Formed Bearish Double Bottom

September 16, 2018 - By Kristen Paramore

The chart of AC Immune SA (ACIU) shows a double bottom with $7.61 target or 6.00 % below today’s $8.10 share price. The 7 months chart pattern indicates high risk for the $545.64M company. It was reported on Sep, 16 by If the $7.61 price target is reached, the company will be worth $32.74 million less. Double bottoms are rare but powerful chart patterns.

The stock decreased 3.69% or $0.31 during the last trading session, reaching $8.1. About 58,121 shares traded. AC Immune SA (NASDAQ:ACIU) has declined 19.43% since September 16, 2017 and is downtrending. It has underperformed by 35.05% the S&P500.

Analysts await AC Immune SA (NASDAQ:ACIU) to report earnings on November, 12. They expect $-0.26 earnings per share, down 62.50 % or $0.10 from last year’s $-0.16 per share. After $-0.20 actual earnings per share reported by AC Immune SA for the previous quarter, Wall Street now forecasts 30.00 % negative EPS growth.

More news for AC Immune SA (NASDAQ:ACIU) were recently published by:, which released: “AC Immune Announces Important Clinical Milestones for ACI-24 Vaccine in Alzheimer’s Disease and Down Syndrome” on August 20, 2018.‘s article titled: “Recent Analysis Shows STMicroelectronics NV, Jagged Peak Energy, Inovalon, AC Immune SA, Repligen, and …” and published on August 22, 2018 is yet another important article.

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has market cap of $545.64 million. The Company’s SupraAntigen and Morphomer platforms generates antibodies and small molecules that selectively bind to misfolded proteins to address neurodegenerative indications, such as AlzheimerÂ’s , ParkinsonÂ’s, down syndrome, and glaucoma diseases. It currently has negative earnings. The companyÂ’s lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase 3 clinical studies.

AC Immune SA (NASDAQ:ACIU) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.